Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (270)	4/5/2002 1:55:27 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 887

Telik Announces Presentations at AACR Meeting SOUTH SAN FRANCISCO, Calif., April 5 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK - news) announced presentations on its TRAP(TM) chemogenomics technology and potential new applications of TRAP in oncology, and its TLK286 product candidate for the treatment of cancer, at the annual meeting of the American Association for Cancer Research (AACR) in San Francisco. On Sunday, April 7 from 8:00 a.m. to 12:00 noon, scientists from Telik and the University of Arizona Cancer Center will present ``Efficient Discovery of Novel Small Molecule Cancer Drugs using Telik's Target-Related Affinity Profiling (TRAP(TM)) Technology'' (Abstract # 191, poster session Chemistry 1 - Proteomics). TRAP is a chemogenomic drug discovery technology that enables the identification of pharmaceutically active compounds for a biologic target after screening as few as 200 computationally selected compounds rather than the hundreds of thousands of compounds that are typically used with alternative automated screening technologies. Telik has used TRAP to assist in the discovery of TLK286, its novel anticancer drug candidate currently in multiple Phase 2 clinical trials; TLK 199, entering Phase 1-2a testing for myelodysplastic syndrome, as well as the earlier stage compounds in its product pipeline. In addition, Telik is reporting at the AACR meeting early success in its collaboration with the Arizona Cancer Center in the identification of active molecules for a variety of cancer targets. ``TRAP is well-suited for post-genomic cancer drug discovery since it provides an efficient and rapid means of identifying active compounds across a wide diversity of targets,'' said Robert T. Lum, Ph.D., Vice President, Preclinical Development. ``It is also a means for accelerating the translation of basic cancer research results to clinical applications.'' On Tuesday, April 9 from 1:00 p.m. to 5:00 p.m., Telik scientists will present ``TLK286-Induced Activation of the Stress Response Apoptotic Signaling Pathway'' (Abstract # 4772, poster session New Targets - New Agents 2). TLK286 is in Phase 2 testing in colorectal, ovarian, non-small cell lung and breast cancer. TLK 286 is activated by glutathione S-transferase (GST) P1-1, an enzyme which is over-expressed in many types of human cancers. Elevated GST P1-1 levels also are correlated with the development of resistance to many commonly used chemotherapeutic drugs. Upon activation, TLK286 triggers an intracellular process known as apoptosis, or programmed cell death. ``Features of the apoptotic mechanism of TLK286 in cancer cells are unique and its activation by GST P1-1 suggest that TLK286 may be a less toxic and more specific anti-cancer agent than current cancer drugs,'' said James G. Keck, Ph.D., Vice President, Biology Research.